Moderna, an American pharmaceutical company that developed the new coronavirus vaccine, has announced that it will be able to supply 200 million doses to the United States by the end of June.
Pfizer, a major pharmaceutical company, has also revealed that it will be able to supply 200 million doses by the end of May, earlier than initially expected.
The American pharmaceutical company Moderna announced on the 26th that it has supplied more than 30 million doses of the new coronavirus vaccine, which has been inoculated since last month, to the United States.
On top of that, the future supply is expected to reach 100 million by the end of March and 200 million by the end of June.
Meanwhile, pharmaceutical giant Pfizer CEO Albert Bourla told US media that 200 million doses of vaccines under a supply contract with the US government are expected to be available by the end of May, earlier than initially expected.
The reason is that the US media has officially acknowledged that the amount of vaccine contained in a bottle of Pfizer's vaccine is higher than originally expected for 5 doses, and that US regulators can also inoculate 6 doses.
In the United States, vaccine supply is in short supply in some states and large cities, and vaccination is delayed, so it is a challenge to expand vaccination by prompt supply of vaccine.